Characteristics of patients infected by HIV and healthy controls
| Variable | Healthy controls (n=32) | HIV infected patients (n=61) | p Value |
|---|---|---|---|
| Age (years) | 30.9 ( 7.9) | 32.7 (5.0) | |
| Previous drug parenteral users (n, %) | 0 (0) | 45 (73.7) | |
| Time of evolution of HIV infection (months) | 62.7 (43.2) | ||
| CD4+ cells (cells × 106/l) | 289.4 (351.8) | ||
| Virus load (copies × 103/mm3) | 108.2 (258.5) | ||
| Stage of HIV infection (n, %) | |||
| A | 21 (34.4) | ||
| B1-150 | 14 (23.0) | ||
| C1-150 | 26 (42.6) | ||
| Antiretroviral treatment (n, %)1-151 | 36 (59.0) | ||
| Weight (kg) | 76.2 (13.5) | 63.3 (9.5) | < 0.01 |
| Body mass index (kg/m2) | 26.0 (4.4) | 22.2 (3.0) | < 0.01 |
| Triceps skinfold thickness (cm) | 16.5 (7.7) | 8.2 (3.6) | < 0.001 |
| Mid-arm fat area (cm2) | 24.2 (13.0) | 10.8 (5.3) | < 0.001 |
| Mid-arm muscle area (cm2) | 44.1 (8.5) | 38.9 (9.2) | < 0.05 |
Values are mean (SD) unless stated otherwise.
↵1-150 Previous opportunistic diseases: pulmonary tuberculosis (8), disseminated tuberculosis (5), oesophageal candidiasis (5), cryptococcal meningitis (2), Kaposi sarcoma,Pneumocystis carinii pneumonia, cytomegalovirus retinitis, recurrent bacterial pneumonia, cerebral toxoplasmosis, and non-Hodgkin lymphoma (1 each).
↵1-151 Antiretroviral treatment: AZT, 10 patients (16.4%); ddI, 3 patients (4.9%); AZT + ddI, 12 patients (19.7%); AZT + ddC, 11 patients (18.0%).